Apellis Pharmaceuticals
APLS
APLS
249 hedge funds and large institutions have $6.65B invested in Apellis Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 67 funds opening new positions, 93 increasing their positions, 65 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
2.74% more ownership
Funds ownership: 86.02% → 88.76% (+2.7%)
17% less call options, than puts
Call options by funds: $92M | Put options by funds: $111M
Holders
249
Holding in Top 10
10
Calls
$92M
Puts
$111M
Top Buyers
| 1 | +$68.3M | |
| 2 | +$64.6M | |
| 3 | +$63.7M | |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$43M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$36.1M |
Top Sellers
| 1 | -$364M | |
| 2 | -$108M | |
| 3 | -$70.5M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$36.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$20.8M |